Shop

Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Breaking News, Industry, Science

1 Jul 2025

Enveric’s EB-003 Shows Dual Mechanism Promise, Paving a New Path in Neuropsychiatric Drug Innovation

Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On June 24, the company announced new data that could significantly broaden...

By Madison Roberts

Breaking News, Press Releases, Science

3 Jun 2025

Enveric’s Patent Win Targets New Frontiers in Sleep Medicine

With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week...

By Madison Roberts

Industry

20 May 2025

Enveric Biosciences Stakes Its Claim in Neurodegeneration Market

Enveric Biosciences is quietly making a bold move into the neurodegenerative disease space with a new class of molecules targeting the critical BDNF/TrKB pathway. While still in early stages, this...

By Madison Roberts

Health & Wellness

19 May 2025

Healing Beyond Addiction: New Research Shows Family Relationships Key to Lasting Recovery

Family healing plays a critical role in overcoming addiction, increasing recovery success rates by up to 50%. Despite this, a severe shortage of mental health professionals leaves many Texans without...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Healing, Health & Wellness

28 Apr 2025

The New Epidemic: How Trauma and Digital Exposure Are Shaping a Teen Mental Health Crisis

The mental health of today's teens is under unprecedented strain, with trauma and digital saturation driving record levels of anxiety, depression, and suicidal ideation. In “Impact of Trauma and Digital...

By Madison Roberts

Industry

8 Apr 2025

No More Silence: The Opioid Epidemics Alarming Impact on Women

Women are facing a silent crisis in the opioid epidemic, with overdose deaths among women aged 30–64 skyrocketing by 260% since 1999. Beyond the statistics lie the stories of mothers,...

By Madison Roberts

Industry, Psychedelic Titans, Science

31 Mar 2025

The Future of Psychedelics: Why Next-Generation Molecules Will Win

The psychedelic industry is undergoing a major transformation. With new, non-hallucinogenic compounds on the rise, companies like Enveric Biosciences, Delix Therapeutics, and Gilgamesh Pharmaceuticals are leading the way in developing...

By Madison Roberts

Breaking News, Finance, Press Releases

25 Feb 2025

Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

Enveric Biosciences (NASDAQ: ENVB) has received its first U.S. patent for the EVM401 Series, a collection of non-hallucinogenic compounds derived from mescaline. These novel therapeutics target multiple neurological receptors associated...

By Madison Roberts

Culture, Healing, Health & Wellness

5 Feb 2025

Microdosing & Women’s Hormones: A Revolutionary Approach to Healing

For too long, women’s health has been reduced to symptom management—birth control, hormone patches, and endless supplements. But what if true healing isn’t about masking symptoms, but restoring balance at...

By Madison Roberts

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.